1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
awt020 Cancer	Shanghai Junshi Bioscience Co., Ltd.	P1	CC (43)
b1962 Cancer	Tasly Biopharmaceuticals Co., Ltd.	P1	CC (43)
bay2927088 Cancer	Bayer	P2	CC (43)
bd0801 Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	CC (43)
Bio-106 Cancer	BiOneCure Therapeutics Inc.	P1/2	CC (43)
Bpi-421286 Cancer	Betta Pharmaceuticals Co., Ltd.	P1	CC (43)
br1733 Cancer	Shanghai Blueray Biopharma Co., Ltd.	P1/2	CC (43)
Car-M-C-Met Cell Intraperitoneal Infusion Cancer	Peking Union Medical College Hospital	P1	CC (43)
cb307 Cancer	Crescendo Biologics Ltd.	P1	CC (43)
Cea Car-T Cells Cancer	Chongqing Precision Biotech Co., Ltd	P1	CC (43)
Cilansetron Cancer	EMD Serono Research & Development Institute, Inc.	P1	CC (43)
Claturafenib Cancer	Pfizer	P1	CC (43)
Cmab017 Cancer	Taizhou Mabtech Pharmaceutical Co.,Ltd	P1	CC (43)
com503 Cancer	Compugen Ltd	P1	CC (43)
ct-95 Cancer	Context Therapeutics Inc.	P1	CC (43)
cvl237 tablets Cancer	Convalife (Shanghai) Co., Ltd.	P2	CC (43)
deg6498 Cancer	Degron Therapeutics Co.	P1	CC (43)
Docetaxel Polymeric Micelles For Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	CC (43)
Envofolimab Cancer	Jiangsu Simcere Pharmaceutical Co., Ltd.	P2	CC (43)
Fam-Trastuzumab Deruxtecan-Nxki Cancer	Strata Oncology	P2	CC (43)
Fluoroglutamine (2S,4R) Cancer	Memorial Sloan Kettering Cancer Center	P1	CC (43)
Fosdesdenosine Sipalabenamide Cancer	NuCana plc	P1/2	CC (43)
Furuitinib Cancer	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P1	CC (43)
G 207 Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Giga-564 Cancer	GigaGen, Inc.	P1	CC (43)
Girentuximab Cancer	M.D. Anderson Cancer Center	P1/2	CC (43)
Glutathione Cancer	The First Affiliated Hospital of Zhengzhou University	P1	CC (43)
Hafnium Oxide Cancer	Nanobiotix	P1	CC (43)
her3-dxd Cancer	Daiichi Sankyo	P2	CC (43)
hro761 Cancer	Novartis Pharmaceuticals	P1	CC (43)
Hrs-2189 Cancer	Shandong Suncadia Medicine Co., Ltd.	P1	CC (43)
Human Single Chain Il-12 Mrna-Multiple Dose Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1	CC (43)
Icp-033 Cancer	Beijing InnoCare Pharma Tech Co., Ltd.	P1	CC (43)
Icp-189 Cancer	Beijing InnoCare Pharma Tech Co., Ltd.	P1	CC (43)
Icvb-1042 Cancer	IconOVir Bio	P1	CC (43)
im-1021 Cancer	Immunome, Inc.	P1	CC (43)
IMA401 Cancer	Immatics Biotechnologies GmbH	P1	CC (43)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cdh6(Cadherin 6, K-Cadherin (Foetal Kidney), Cadherin 6 Type 2)], Humanized Monoclonal Antibody Conjugated To Deruxtecan, Comprising A Linker And A Camptothecin Derivative Cancer	Daiichi Sankyo	P2	CC (43)
Inupadenant Cancer	iTeos Belgium SA	P1/2	CC (43)
INX315 Cancer	Incyclix Bio	P1/2	CC (43)
JL19001 Cancer	Jecho Biopharmaceuticals Co., Ltd.	P1	CC (43)
js007 Cancer	Shanghai Junshi Bioscience Co., Ltd.	P1	CC (43)
JS014 Cancer	Anwita Biosciences	P1	CC (43)
kb707 Cancer	Krystal Biotech, Inc.	P1/2	CC (43)
Lazertinib Cancer	Abion Inc	P2	CC (43)
Lispro-Ph20 Component Rhuph20 Cancer	Bristol-Myers Squibb	P1/2	CC (43)
lm-168 Cancer	LaNova Medicines Limited	P2	CC (43)
ltc004 Cancer	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CC (43)
LY 3410738 Cancer	Eli Lilly and Company	P1	CC (43)
ly4052031 Cancer	Eli Lilly and Company	P1	CC (43)

Showing 401 to 450 of 1,379 assets

PreviousPage 9 of 28Next